Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.249
+0.025 (11.08%)
At close: Apr 28, 2026, 4:00 PM EDT
0.249
-0.000 (-0.04%)
Pre-market: Apr 29, 2026, 5:49 AM EDT
Azitra Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
4.03M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 5.07M |
| 60 Degrees Pharmaceuticals | 1.41M |
| SciSparc | 1.31M |
| VivoSim Labs | 142.00K |
| AIM ImmunoTech | 88.00K |
| Pulmatrix | 3.00K |
| Soligenix | 2.34K |
AZTR News
- 22 hours ago - Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris - PRNewsWire
- 5 weeks ago - Why Are Shares Of Azitra Rising? - Benzinga
- 5 weeks ago - Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million - PRNewsWire
- 6 weeks ago - Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement - PRNewsWire
- 7 weeks ago - Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders - PRNewsWire
- 2 months ago - Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates - PRNewsWire
- 2 months ago - Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash - PRNewsWire
- 2 months ago - Azitra, Inc. to Present at BIO Investment & Growth Summit - PRNewsWire